Meet the Speakers

  • Philip Home, UK  |  Congress Chairperson

    Philip Home, UK | Congress Chairperson

    Prof. Philip Home trained in medicine at Oxford University and Guy's Hospital, coming under the influence of Harry Keen, and thus gravitating into diabetes research. Continuing this research career in Newcastle upon Tyne, initially under the guidance of George Alberti, he has published over 450 papers, books and reviews on aspects of diabetes, from basic studies on metabolism to RCTs of new therapies, and aspects of the organization and delivery of diabetes health-care.
  • Stephanie Amiel, UK

    Stephanie Amiel, UK

    Stephanie Amiel is Professor of Diabetes Research at King’s College London and consultant physician at King’s College Hospital in the UK. She trained at Guy’s Hospital, London with Harry Keen, and started her research career at Yale with Robert Sherwin and Bill Tamborlane.
  • Bärbel Aschemeier, Germany

    Bärbel Aschemeier, Germany

    Dr. Aschemeier is a study coordinator at the Kinder- und Jugendkrankenhaus AUF DER BULT in Hannover, Germany.  Beside the coordination of various mono- and multicentric national and international studies she was the project coordinator of the SWEET-project till 2013 is currently involved in INNODIA to establish an accreditation system for clinical trial centers in T1D prevention and intervention inside the EU. 
  • Marianne Bach Treppedahl, Denmark

    Marianne Bach Treppedahl, Denmark

    Dr. Treppendahl joined Novo Nordisk in 2015 and has worked in different parts of the GLP-1 portfolio. In her current position Dr. Treppendahl mainly works with the new disease areas. Dr. Treppendahl obtained her medical degree from the University of Copenhagen in 2004. She has more than 10 years of clinical experience in internal medicine and hematology. She holds a PhD in Hematology from the University of Copenhagen and has a strong research background with several publications in high-ranking journals.

  • Hans DeVries, The Netherlands/Germany

    Hans DeVries, The Netherlands/Germany

    J. Hans DeVries obtained board licenses in Internal Medicine and Endocrinology at the VU University Medical Centre, Amsterdam, the Netherlands. His PhD thesis (2003) was entitled ‘Subcutaneous and Intraperitoneal Insulin Delivery in Type 1 Diabetes’. 
  • Nick Freemantle, UK

    Nick Freemantle, UK

    Nick Freemantle is Professor of Clinical Epidemiology and Biostatistics at University College London (UCL), UK, and Director of UCL’s Comprehensive Clinical Trials Unit, which undertakes high-quality, randomized trials and diagnostic studies in a real-world setting to inform clinical practice. He leads a program of research examining healthcare delivery and practice, and related methodology. 
  • Ramon Hovorka, UK

    Ramon Hovorka, UK

    Roman Hovorka is Professor of Metabolic Technology Research at the Institute of Metabolic Science and Department of Paediatrics at University of Cambridge. He made seminal contributions to diabetes technology including the “Artificial Pancreas”, a device that delivers insulin in glucose responsive fashion. 
  • Baruch Itzhak, Israel

    Baruch Itzhak, Israel

    Dr. Baruch Itzhak is a specialist in Family Medicine and Diabetologist at Clalit Health Services; Haifa district; Israel.  He was graduated for medicine at Tel-Aviv university in 1986. He received his medical degree of Family Medicine at the Technion faculty of medicine, Haifa in 1994.
  • Nikolaus Marx, Germany

    Nikolaus Marx, Germany

    Nikolaus Marx, born in 1968, is Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany. He received his medical training at the Universities of Mainz, Genf (Switzerland) and Düsseldorf, obtaining his MD in 1994.
  • Greg Meiffren, France

    Greg Meiffren, France

    Greg Meiffren, PhD, is Director of Clinical Development, PKPD and Biology at Adocia (Lyon, France). He joined the company in 2009. He is also project leader on BioChaperone Lispro, an ultra-rapid insulin lispro formulation and BioChaperone Combo, a co-formulation of insulin glargine and insulin lispro.
  • Ulrik Pedersen-Bjergaard, Denmark

    Ulrik Pedersen-Bjergaard, Denmark

    Ulrik Pedersen-Bjergaard is Chief Physician at the Department of Endocrinology and Nephrology, Nordsjællands Hospital Hillerød and Professor at the University of Copenhagen, Denmark. He is a certified specialist in general internal medicine and endocrinology and holds a Doctor of Medical Science (DMSc). 
  • Eberhard Standl, Germany

    Eberhard Standl, Germany

    Professor Eberhard Standl is Professor of Medicine, endocrinologist and angiologist at the Munich Diabetes Research Group e.V. at Helmholtz Centre. He has produced 627 original papers, review articles, textbook chapters and monographs. Professor Standl is the Past President of IDF Europe, German Diabetes Association and German Diabetes Union and Past Vice President of EASD and IDF.
  • John Wilding, UK

    John Wilding, UK

    John Wilding leads Clinical Research into Obesity, Diabetes and Endocrinology at the University of Liverpool. He graduated from Southampton University in 1985, where he continued his clinical training until moving to the Royal Postgraduate Medical School at Hammersmith Hospital, London where he undertook specialist training in Diabetes and Endocrinology, and three years laboratory-based research into the neurobiology of obesity and diabetes. 
  • Fred Yang, USA

    Fred Yang, USA

    Dr. Fred Yang has 20 years of experience in clinical research and drug development, with expertise focusing on statistics and quantitative science. He assumed increasing responsibilities in both Big Pharma (Abbott, Pharmacia, GSK etc.) and small biotech (Discovery Labs, KBP Biosciences), overseeing biostatistics as well as trial conduct and strategic planning.